Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.